Evaluating differences in atrophy rates in patients with or without biological disease-modifying drugs, such as anti-interleukin-6 receptor therapy, may be necessary to determine whether preventing MRI activation in the spinal cord or subclinical active lesions prevents brain atrophy in patients with AQP4 + NMOSD. This evidence concerns the gene AQP4 and Brain atrophy.